Animal Models for the Study of Human Disease identifies important animal models and assesses the advantages and disadvantages of each model for the study of human disease. The first section addresses how to locate resources, animal alternatives, animal ethics and related issues, much needed information for researchers across the biological sciences and biomedicine.The next sections of the work offers models for disease-oriented topics, including cardiac and pulmonary diseases, aging, infectious diseases, obesity, diabetes, neurological diseases, joint diseases, visual disorders, cancer, hypertension, genetic diseases, and diseases of abuse. Organized by disease orientation for ease of searchability Provides information on locating resources, animal alternatives and animal ethics Covers a broad range of animal models used in research for human disease

The world has recorded losses in terms of human life as well as extensive time spent in experimentation with development of new drugs, elucidation of disease mechanism(s), and therapeutic agent discovery. Ethical and legal issues cojoin in slowing down scientific discoveries in medicine and biology. The past two (2) decades, therefore, have seen tremendous attempts that largely are successful in developing animal models with the characteristics of mimicking, approximating, or expressing transplanted human organs/tissues. These models or rather approaches seem to be fast, cost-effective, and easy to maintain compared to primates. This book is a collection of expert essays on animal models of human diseases of global interest. A visible objective of the book is to provide real-time experimental approach to scientists, clinicians, ethicists, medicolegal/medical jurisprudence workers, immunologists, postgraduate students, and vaccinologists and informative and multidisciplinary approach for the identification of new therapeutic targets and biomarkers using animal models as well as investigating the pathogenesis and therapeutic strategies of human diseases. An increased understanding of the genetic, molecular, and cellular mechanisms responsible for the development of human diseases has laid out the foundation for the development of rational therapies mainly with animal models.

This two-volume work gathers together the diverse information presently available on spontaneous animal models of human disease. In addition to providing a comprehensive review of existing models, the book presents many previous unpublished new models. The scope of this work is limited to spontaneous models. Neoplasia, infectious diseases including parasitism, and nutritionally induced or other types of experimental models have not been included. The sixteen parts of the book are alphabetically arranged according to organ system with over 230 authors contributing to the overall effort. In addition to many illustrations, the book features an extensive bibliography.

The collection of systems represented in this volume is a unique effort to reflect the diversity and utility of models used in biomedicine. That utility is based on the consideration that observations made in particular organisms will provide insight into the workings of other, more complex systems. This volume is therefore a comprehensive and extensive collection of these important medical parallels.

The National Institute of Allergy and Infectious Diseases (NIAID) gives the highest priority to developing countermeasures against bioterrorism agents that are highly infective when dispersed in aerosol form. Developing drugs to prevent or treat illnesses caused by bioterrorism agents requires testing their effectiveness in animals since human clinical trials would be unethical. At the request of NIAID, the National Academies conducted a study to examine how such testing could be improved. Overcoming Challenges to Develop Countermeasures Against Aerosolized Bioterrorism Agents provides recommendations to researchers on selecting the kinds of animal models, aerosol generators, and bioterrorism agent doses that would produce conditions that most closely mimic the disease process in humans. It also urges researchers to fully document experimental parameters in the literature so that studies can be reproduced and compared. The book recommends that all unclassified data on bioterrorism agent studies-including unclassified, unpublished data from U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)-be published in the open literature. The book also calls on the U.S. Food and Drug Administration to improve the process by which bioterrorism countermeasures are approved based on the results of animal studies.

Nonclinical Safety Assessment Nonclinical Safety Assessment A Guide to International Pharmaceutical Regulations Bringing a new drug to market is a costly time-consuming process. Increased regional and international regulation over the last twenty years, while necessary, has only served to amplify these costs. In response to this escalation, developmental strategies have shifted towards a more global approach. In order to create the most cost-effective and safe processes, it is critical for those bringing drugs to market to understand both the globally accepted regulations and the local variations. Nonclinical Safety Assessment: A Guide to International Pharmaceutical Regulations provides a practical description of nonclinical drug development regulations and requirements in the major market regions. It includes: ICH – the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use National regulations, including US FDA, Canada, Mercosur and Brazil, South Africa, China, Japan, India and Australia Repeated dose toxicity studies Carcinogenicity; Genotoxicity; Developmental and reproductive toxicology; Immunotoxicology Biotechnology-derived pharmaceuticals Vaccine development Phototoxicity and photocarcinogenicity Degradants, impurities, excipients and metabolites Primarily intended for those professionals actively involved in the nonclinical and clinical development of a pharmaceutical product, including toxicologists, pharmacologists, clinicians and project managers, this book provides a roadmap for successful new drug approval and marketing.

Cellular and Animal Models in Human Genomics Research provides an indispensable resource for applying comparative genomics in the annotation of disease-gene associated variants that are identified by human genomic sequencing. The book presents a thorough overview of effective protocols for the use of cellular and animal modeling methods to turn lists of plausible genes into causative biomarkers. With chapters written by international experts, the book first addresses the fundamental aspects of using cellular and animal models in genetic and genomic studies, including in-depth examples of specific models and their utility, i.e., yeast, worms, flies, fish, mice and large animals. Protocols for properly conducting model studies, genomic technology, modeling candidate genes vs. genetic variants, integrative modeling, utilizing induced pluripotent stem cells, and employing CRISPR-Cas9 are also discussed in-depth. Provides a thorough, accessible resource that helps researchers and students employ cellular and animal models in their own genetic and genomic studies Offers guidance on how to effectively interpret the results and significance of genetic and genomic model studies for human health Features chapters from international experts in the use of specific cellular and animal models, including yeast, worms, flies, fish, mice, and large animals, among other organisms